EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach

Tayebeh Cheraghi-Shavi iD, Razieh Jalal iD, Zarrin Minuchehr

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0289535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Tayebeh Cheraghi-Shavi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Iran. Hauptthemen laut MEDLINE: Galectin 4, Colorectal Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ferdowsi University of Mashhad.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance to oxaliplatin is considered as the primary reason for failure in colorectal cancer (CRC) therapy. Identifying the underlying resistance mechanisms may improve CRC treatment. The present study aims to identify the key genes involved in acquired oxaliplatin-resistant in CRC by confirming the oxaliplatin resistance index (OX-RI). To this aim, two public microarray datasets regarding oxaliplatin-resistant CRC cells with different OX-RI, GSE42387, and GSE76092 were downloaded from GEO database to identify differentially expressed genes (DEGs). The results indicated that the OX-RI affects the gene expression pattern significantly. Then, 54 common DEGs in both datasets including 18 up- and 36 down-regulated genes were identified. Protein-protein interaction (PPI) analysis revealed 13 up- ( MAGEA6 , TGM2 , MAGEA4 , SCHIP1 , ECI2 , CD33 , AKAP12 , MAGEA12 , CALD1 , WFDC2 , VSNL1 , HMGA2 , and MAGEA2B ) and 12 down-regulated ( PDZK1IP1 , FXYD3 , ALDH2 , CEACAM6 , QPRT , GRB10 , TM4SF4 , LGALS4 , ALDH3A1 , USH1C , KCNE3 , and CA12 ) hub genes. In the next step, two novel up-regulated hub genes including ECI2 and SCHIP1 were identified to be related to oxaliplatin resistance. Functional enrichment and pathway analysis indicated that metabolic pathways, proliferation, and epithelial-mesenchymal transition may play dominant roles in CRC progression and oxaliplatin resistance. In the next procedure, two in vitro oxaliplatin-resistant sub-lines including HCT116/OX-R4.3 and HCT116/OX-R10 cells with OX-IR 3.93 and 10.06 were established, respectively. The results indicated the up-regulation of TGM2 and HMGA2 in HCT116/OX-R10 cells with high OX-RI and down-regulation of FXYD3 , LGALS4 , and ECI2 in both cell types. Based on the results, TGM2 , HMGA2 , FXYD3 , and LGALS4 genes are related to oxaliplatin-resistant CRC and may serve as novel therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Galectin 4Colorectal NeoplasmsHumansOxaliplatinSystems BiologyBiomarkers, TumorTranscription FactorsGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmComputational BiologyMembrane ProteinsNeoplasm ProteinsAldehyde Dehydrogenase, MitochondrialDodecenoyl-CoA IsomeraseMembrane GlycoproteinsAntigens, Neoplasm

Substanzen

OxaliplatinGalectin 4Biomarkers, TumorTranscription FactorsMembrane ProteinsNeoplasm ProteinsAldehyde Dehydrogenase, MitochondrialFXYD3 protein, humanALDH2 protein, humanECI2 protein, human

Autor:innen und Institutionen

  • Faculty of Science, Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Institute of Biotechnology, Novel Diagnostics and Therapeutics Research Group, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Systems Biotechnology Department, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

ORCID-Profile: Tayebeh Cheraghi-Shavi, Razieh Jalal

Förderung

  • Ferdowsi University of Mashhad

Zitieren

APA

Cheraghi-Shavi, T., Jalal, R., & Minuchehr, Z. (2023). TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach. PLOS ONE. https://doi.org/10.1371/journal.pone.0289535

Vancouver

Cheraghi-Shavi T, Jalal R, Minuchehr Z. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach. PLOS ONE. 2023. doi:10.1371/journal.pone.0289535

BibTeX
@article{CheraghiShavi2023,
  author = {Cheraghi-Shavi, Tayebeh and Jalal, Razieh and Minuchehr, Zarrin},
  title = {TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0289535}
}
Kostenlos starten →